Fourth ac­cel­er­at­ed ap­proval in Duchenne? Sarep­ta gets pri­or­i­ty re­view for gene ther­a­py amid FDA scruti­ny

Sarep­ta is once again on the ac­cel­er­at­ed ap­proval path for a Duchenne drug, pick­ing up a pri­or­i­ty re­view Mon­day morn­ing.

The FDA grant­ed the ac­cel­er­at­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER